Lilly/Amylin submit exenatide
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly/Amylin plan to position their type 2 diabetes agent exenatide for use in patients not achieving goal on oral agents; an NDA for the first-in-class incretin mimetic was submitted June 30. "The initial target population for exenatide does not include patients on insulin," Lilly says. Based on exenatide's novel mechanism, the firms are highlighting its potential as an insulin alternative "that carries a lower risk of hypoglycemia with no weight gain." A National Institutes of Health-sponsored study of exenatide in type 1 diabetes is underway. "The results of that [20-month] exploratory study will determine our next steps in the type 1 diabetes arena," Lilly says...
You may also be interested in...
Approvals In Brief
Lilly/Amylin Byetta clears FDA as first incretin mimetic; GSK readies Boostrix launch following May 3 BLA approval. GlaxoSmithKline’s dopamine agonist Requip (ropinirole) is approved May 4 as the first treatment for restless legs syndrome. More FDA approvals in brief
Diabetes Drug Advances Are Highlight Of NMEs Pending In 2005
Highlights of NME class of 2005 could be advances in diabetes, with Lilly/Amylin’s exenatide and Amylin’s Symlin currently being reviewed and Pfizer’s inhaled insulin Exubera slated for filing early in the year. Other major pending NMEs include J&J’s dapoxetine for premature ejaculation and Solvay’s irritable bowel syndrome agent Calmactin (cilansetron)
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.